Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.66 |
| ▸ | RAF1 | P04049 | 5/20 | 0.66 |
| ▸ | KDR | P35968 | 7/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | KIF5B | P33176 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 3/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15463770 | 0.92 | BRAF (0.68) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL15463614 | 0.87 | KDR (0.73) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL15463602 | 0.83 | EGFR (0.71) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL15463615 | 0.83 | KDR (0.61) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL15463648 | 0.83 | BRAF (0.70) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL1015284 | 0.80 | BRAF (1.00) | BRAFRAF1KDR | |
| SCHEMBL4471428 | 0.80 | FGFR2 (0.70) | BRAFRAF1KDREGFRLCK | |
| SCHEMBL20229657 | 0.78 | KDR (0.74) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL13680204 | 0.78 | KDR (0.73) | BRAFRAF1KDRRETKIF5B | |
| SCHEMBL7485859 | 0.78 | FGFR2 (0.71) | BRAFRAF1KDRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885KDR 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.